The Diuretic-Magnesium Question in Heart Failure

  • L. Alcocer
  • A. J. Reyes
Chapter

Summary

Magnesium deficit must be prevented and treated with particular zeast in chronic congestive heart failure. Besides its usual general consequences, in the case of chronic congestive heart failure under chronic therapy with loop or thiazide-type diuretics magnesium deficit predisposes to (digitalis-induced or not) cardiac arrhythmias, causes resistance to potassium replenishment in patients with hypokalemia, could impair cardiac pump function directly at the cardiac level, and could facilitate (exaggerate) vasoconstriction.

Loop and thiazide-type diuretics increase the renal excretion of magnesium and may conduce to magnesium deficit upon prolonged administration; this possibility is enhanced by the coexistence of factors other than diuretic therapy which may concur to the development of this condition. However, the use of diuretics is mandatory in chronic congestive heart failure. Copharmacotherapy with potassium-retaining diuretics should not be instituted as a routine. Oral magnesium suplementation, correction of concomitant factors conducing to magnesium deficit, and the use of appropriate doses of diuretics appear as the best measures to prevent and/or treat diuretic-induced deficit in patients with chronic congestive heart failure and normal renal function..

Keywords

Congestive Heart Failure Loop Diuretic Serum Magnesium Chronic Congestive Heart Failure Serum Magnesium Concentration 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Schocken DD, Arrieta MI, Leaverton PE, Ross EA. (1992) Prevalence and mortality of congestive heart failure in the United States. J Am Coll Cardiol;20: 301–306.CrossRefGoogle Scholar
  2. 2.
    Cowie MR Mosterd A Wodd DA, Deckerst PA. Poole-Wilson PA, Sutton GC, Grobbee DE. (1997) The epidemiology of heart failure. Eur Heart J;18: 208–225.Google Scholar
  3. 3.
    Ho KKL, Pinski Jl, Kannel WE. (1993) The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol,22(Suppl A): 6A-13A.CrossRefGoogle Scholar
  4. 4.
    The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fraction and congestive heart failure. N Engl J Med (1991);325: 293–302.Google Scholar
  5. 5.
    Reyes AJ. (1995) Pathophysiological basis of the use of diuretics in congestive heart failure. Prog Pharmacol Clin Pharmacol;10: 75–85.Google Scholar
  6. 6.
    Achhammer I. (1990) Long-term efficacy and tolerance of torasemide in congestive heart failure. Prog Pharmacol CI in Pharmacol;8: 127–136.Google Scholar
  7. 7.
    Dixon DW, Barwolf-Gohilke C, Gunnar RM. (1981) Comparative efficacy and safety of bumetanide and furosemde in long-term treatment of edema due to congestive heart failure. J Clin Pharmacol;21: 680–687.Google Scholar
  8. 8.
    Düsing R, Piesche L. (1990) Second line therapy of congestive heart failure with torasemide. Prog Pharmacol Clin Pharmacol;8: 381–391.Google Scholar
  9. 9.
    Oversohl K, Mehrabian G, Hanisch M, Schmitz H. (1985) Muzolimine as monotherapy in the treatment of patients with congestive heart failure. Z KardiolJ;74(Suppl2): 27–31.Google Scholar
  10. 10.
    Podszus T, Piesche L. (1990) Effect of torasemide on pulmonary and cardiac hemodynamics after oral treatment of chronic heart failure. Prog Pharmacol Clin Pharmacol;8/1: 151–166Google Scholar
  11. 11.
    Sherman LG, Liang C, Baumgardner S, Charuzi Y, Chardo F, Kim CS. (1986) Piretanide, a potent diuretic with potassium-sparing properties, for the treatment of congestive heart failure. Clin Pharmacol Then;40: 587–594CrossRefGoogle Scholar
  12. 12.
    Stauch M, Stiehl L. (1990) Controlled, double-blind clinical trial of the efficacy and tolerance of torasemide in comparison with furosemide in patients with congestive heart failure-a multicenter study Prog Pharmacol Clin Pharmacol;8/1: 121–126Google Scholar
  13. 13.
    Verho M, Bückert C, Freude J, Laeger S, Pahnke K. (1985) The effects of piretanide, a potassium stable diuretic, on serum electrolytes in patients with congestive heart failure. Pharmatherapeutica;4: 288–295Google Scholar
  14. 14.
    Haerer W, Bauer U, Sultan N, Cernoch K, Fehske KJ, Hetzel M, Stauch M, Hombach V. (1990) Acuteand chronic effects of a diuretic monotherapy with piretanide in congestive heart failure-a placebo controlled trial. Cardiovasc Drugs Ther:4: 515–522CrossRefGoogle Scholar
  15. 15.
    Schäfer CE and Sievert H. (1987) Treatment of chronic congestive heart failure: effect of hydrochlorothiazide and trimaterene on cardiac performance. In: Andreucci VE and Dal Canton A, (eds.),Diuretics: Basic, Pharmacologic and Clinical Aspects. Boston: Martinus Nijhoff, pp 350–352CrossRefGoogle Scholar
  16. 16.
    Reyes AJ. (1987) Aspects of the mechanism of action of diuretics in heart failure. In: Andreucci VE, Dal Canton A, (Eds/ Diuretics: Basic,Pharmacologic and Clinical Aspects. Boston, Martinus Nijhoff; pp 344–349CrossRefGoogle Scholar
  17. 17.
    Reyes AJ. (1987) Diuretics in heart failure. In: Puschett JB, Greenberg A, (eds.), Diuretics II: Chemistry,Pharmacology, and Clinical Applications. Elsevier Science, New York,; 332–344Google Scholar
  18. 18.
    Reyes AJ. (1988) Therapy with diuretics in congestive heart failure. Prog Pharmacol Clin Pharmacol;6/3: 167–192Google Scholar
  19. 19.
    Reyes AJ: (1992) Actions of diuretics on the functional processes of congestive heart failure: from facts to heuristic hypotheses. Prog Pharmacol Clin Pharmacol;9: 441–460Google Scholar
  20. 20.
    Reyes AJ. (1993) Loop diuretics versus others in the treatment of congestive heart failure after myocardial infarction,Cardiovasc Drugs Ther;7: 869–876CrossRefGoogle Scholar
  21. 21.
    Reyes AJ. (1993) The treatment of congestive heart failure with diuretics: turning points and unresolved issues. J Heart Failure, (Suppl), abstract 34Google Scholar
  22. 22.
    Gillies A Morgan T, Myers J. (1980) Comparison of piretanide and chlorothiazide in the treatment of cardiac failure. Med J Aust;1: 170–172Google Scholar
  23. 23.
    Reyes AJ, Leary WP, Crippa G, Alcocer L. (1995) Untoward actions of diuretics in congestive heart failure. Prog Pharmacol Clin Pharmacol;10/3: 132–158Google Scholar
  24. 24.
    Mountokalakis T, Dourakis D, Mayopoulou-Symvoulidou D. (1989) Magnesium-sparing diuretics. 1989, in Itokawa Y, Durlach J, (eds.),Magnesium in Health and Disease. John Libbey: London, 409–413Google Scholar
  25. 25.
    Lasserre B, Spoerri M, Theubet MP, Mollet V. (1997) Magnesium dysbalance in clinical practice: 7-year experience from the Donmag study,Adv Mag Res;1:.281–293Google Scholar
  26. 26.
    Golf SW. (1994) Biochemistry of magnesium in man. In: Golf S, Dralle D, Vecciet TL.,(eds),Magnesium 1993.London: John Libbey, 31–41Google Scholar
  27. 27.
    Lim P, Jacob E. (1972) Magnesium deficiency in patients on long-term diuretic therapy for heart failure. Br Med J;3: 620–622CrossRefGoogle Scholar
  28. 28.
    Abraham AS, Rosenman D, Meshulam Z, Balkin J, Zion M, Eylath U. (1986) Intracellular cations and diuretic therapy following acute myocardial infarction. Arch Intern Med;146: 1301–1303CrossRefGoogle Scholar
  29. 29.
    Ryan MP, Ryan MF, Counihan TG. (1981) The effects of diuretics on lymphocyte magnesium and potassium. Acta Med ScandSuppl 647: 153–161Google Scholar
  30. 30.
    Schwinger RG, Antoni DH. (1992) Triamterene may preserve lymphocyte magnesium and potassium in patients with congestive heart failure. Magnesium Res;5: 29–32Google Scholar
  31. 31.
    Ryzen E, Elkayan U, Rude Rk. (1986) Low blood mononuclear cell magnesium in intensive cardiac care unit patients. Am Heart J;11: 475–480CrossRefGoogle Scholar
  32. 32.
    Sueta CA, Patterson JH, Adams KF. (1995) Antiarrhythmic action of pharmacological administration of magnesium in heart failure: a critical review of new data Magnesium Res;8: 389–401Google Scholar
  33. 33.
    Gottlieb SS, Baruch L, Kulin ML, Bernstein JL, Fisher ML, Packer M. (1990) Prognostic importance of the serum magnesium concentration in patients with congestive heart failure. J Am Coll Cardiol;16: 821–831CrossRefGoogle Scholar
  34. 34.
    Wester PO, Dyckner T. (1986) Intracellular electrolytes in cardiac failure. Acta Med Scand;707: 33–36Google Scholar
  35. 35.
    Gottlieb SS. (1989) Importance of magnesium in congestive heart failure. Am J Cardiol;63: 39G-42GGoogle Scholar
  36. 36.
    Spisak V. (1996) Serum and urinary concentrations of magnesium in patients with chronic heart failure. Vnitr-Lek;42: 680–683Google Scholar
  37. 37.
    Altura BM, Altura BT. (1977) Magnesium metabolism, atherogenesis and cardiovascular pathobiology. Adv Magnes Res;1: 28–37Google Scholar
  38. 38.
    Zoppi F, De-Gasperi A, Guagnellini E, Marocchi A, Mineo E, Pazzucconi F, Rossi C, Turrini D. (1996) Measurement of ionized magnesium with AVL 988/4 electrolyte analyzer: preliminary analytical and clinical results. Scand J Clin Lab Invest;224: 259–274CrossRefGoogle Scholar
  39. 39.
    Eichhorn EJ, Tandon PK, Di Bianco R, Timmis GC, Fenster Pe Shannon J, Packer M, (1993) Clinical and prognostic significance of serum magnesium concentration in patients with severe chroniccongestive heart failure the PROMISE Study. J Am Coll Cardiol;21: 634–640CrossRefGoogle Scholar
  40. 40.
    Popovtzer MM, Massry SG, Coburn JW, Kleeman CR. (1969) The interrelationship between sodium, calcium and magnesium excretion in advanced renal failure. J Clin Med;731: 763/771Google Scholar
  41. 41.
    Wang RW. (1987) Magnesium deficiency. Pathogenesis, prevalence and clinical implications. Am J Med;82: 24–29CrossRefGoogle Scholar
  42. 42.
    Reyes AJ. (1987) Interactions between magnesium and drugs in congestive heart failure. Magnesium Bull;9: 93–109Google Scholar
  43. 43.
    Alcocer L, Reyes AJ. (1986) Negative effects of risk factor reduction in the heart. Cardiol Clin;4: 153–161Google Scholar
  44. 44.
    Reyes AJ. (1993) Renal excretory profile of loop diuretics: consequence for therapeutic application. J Cardiovasc Pharmacol;41(Suppl 3): S11-S23CrossRefGoogle Scholar
  45. 45.
    Reyes AJ. (1991) Effects of diuretics on outputs and flows of urine and urinary solutes in healthy subjects. Drugs;41(Suppl 3): 35–59CrossRefGoogle Scholar
  46. 46.
    Leary WP, Reyes AJ, van der Byl K. Spironolactone is a facultative diuretic and antimagnesiuretic in man. In: Golf S, Dralle D, Vecciet L, (Eds;, (1984)Magnesium 1993. John Libbey, London 1994, pp 299–302Google Scholar
  47. 47.
    Leary WP, Reyes AJ, Drug interactions with diuretics. S Afr Med J;655: 455–461Google Scholar
  48. 48.
    Leary WP, Reyes AJ, Van der Byl K. (1984) Effects of a combination of hydrochlorothiazide and amiloride on plasma magnesium in patients with essential hypertension. Magnesium Bull;6: 127–132Google Scholar
  49. 49.
    Reyes AJ, Leary WP, van der Byl K. Response of magnesiuresis to furosemide-amiloride and captopril.. In Golf S, Dralle D, Vecciet L, (eds.), (1994);Magnesium 1993 London: John Libbey, 303/306Google Scholar
  50. 50.
    Crawford RJ, Allman S, Kitchen SP, Richards HH. (1988) A long-term open study of a frusemide/amiloride combination (“Frumil”) in elderly patients with congestive cardiac failure. Curr Med Res 0pin;10: 675–681CrossRefGoogle Scholar
  51. 51.
    Gullestad L, Midtvedt K, Dolva LO, Norselth. (1992) The magnesium loading test: reference values in healthy subjects. Scand J Clin Lab Invest;52: 245–253CrossRefGoogle Scholar
  52. 52.
    Gullestad L; Dolva LO, Waage A, Falch D, Fagerthun H, Kjecshus J. (1992);Magnesium deficiency diagnosed by an intravenous loading test. Scand J Clin Lab Invest 52: 245–253CrossRefGoogle Scholar
  53. 53.
    Webb EL, Godfrey JC, Rosenbaum R, Zisblatt M, Vukobich RA, Neiss ES. (1984) Chlorthalidone- triamterene: a potassium-sparing diuretic combination for the treatment of oedema. J Int Med Res;12: 147–153Google Scholar

Copyright information

© Kluwer Academic Publishers 1997

Authors and Affiliations

  • L. Alcocer
    • 1
  • A. J. Reyes
    • 2
  1. 1.National University of Mexico and Mexico City General HospitalTuxpanMexico
  2. 2.Institute of Cardiovascular TheoryMontevideoUruguay

Personalised recommendations